Tag: CAP37

JC: TICH TICH BOOM? TXA in ICH. St Emlyn’s

TXA. Huh. Good god y’all. What is it good for? Absolutely everything. This appears to be the alternative hypothesis for the TICH-2 study 1, published last week in the Lancet. Off the back of recent

Who gets a Tetanus? You get a Tetanus!

UPDATE – This post still contains relevant information about tetanus, immunisation schedules, and management of clinical tetanus, however the UK guidelines have changed. Please continue to read this post, but then check out this update for

JC: Kicking against the prick: Systematic Review of stroke thrombolysis

I think it’s probably fair to say that stroke physicians and emergency physicians disagree about the utility of thrombolysis in acute ischaemic stroke. They love it, probably because of its occasionally amazing effects in restoring

JC: Platelets for Intracranial Haemorrhage. St.Emlyn’s

The management of stroke is one of those topics that attracts a great deal of controversy in the #FOAMed world, and with good reason. The questions around the use of thrombolysis for acute cerebral infarction,

JC: Intra-arterial treatment for Stroke

Here at St.Emlyn’s the whole team loves a good stroke trial as they always throw up controversies and concerns about methods, outcomes and our absolute favourite ‘statistics’. That said, although we love discussing the trials

Dystonia in the Emergency Department

I’m sure we’ve all seen cases like this. A 25 year old lady walks in to the ED complaining of a swollen tongue. She can’t really talk, seems a bit anxious and is quite tearful.

JC: Time is brain…., calling #FOAMagitators. St.Emlyn’s

Streamlining of prehospital stroke management: the golden hour. If you have been happily playing with #FOAM for the last year or two then you must have come across the many excellent articles on the use

J

JC: IST-3

So…. We have just covered the following paper in our journal club at Manchester Royal Infirmary. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60768-5/abstract The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic

Translate »